• Hypertrophic Cardiomyopathy (HCM)
  • Vaccines: 2023 Year in Review
  • Eyecare
  • Urothelial Carcinoma
  • Women's Health
  • Hemophilia
  • Heart Failure
  • Vaccines
  • Neonatal Care
  • Type II Inflammation
  • Substance Use Disorder
  • Gene Therapy
  • Lung Cancer
  • Spinal Muscular Atrophy
  • HIV
  • Post-Acute Care
  • Liver Disease
  • Pulmonary Arterial Hypertension
  • Biologics
  • Asthma
  • Atrial Fibrillation
  • Type I Diabetes
  • RSV
  • COVID-19
  • Cardiovascular Diseases
  • Breast Cancer
  • Prescription Digital Therapeutics
  • Reproductive Health
  • The Improving Patient Access Podcast
  • Blood Cancer
  • Ulcerative Colitis
  • Respiratory Conditions
  • Multiple Sclerosis
  • Digital Health
  • Population Health
  • Sleep Disorders
  • Biosimilars
  • Plaque Psoriasis
  • Leukemia and Lymphoma
  • Oncology
  • Pediatrics
  • Urology
  • Obstetrics-Gynecology & Women's Health
  • Opioids
  • Solid Tumors
  • Autoimmune Diseases
  • Dermatology
  • Diabetes
  • Mental Health

FDA Expands Akili's EndeavorRx Game-Based Digital Therapy for ADHD Eligibility to Ages 8-17


As the only FDA-approved, game-based digital therapeutic, EndeavorRx’s eligibility is expected to more than double the number of pediatric patients with ADHD who have a prescription from a healthcare provider, due to the increased age range.

Akili, Inc., a digital medicine company, recently got FDA approval to extend the EndeavorRx® label from 8 to 12-year-olds with inattentive or combined-type ADHD to 13 to 17-year-olds.

As the only FDA-approved, game-based digital therapeutic, EndeavorRx’s eligibility is expected to more than double the number of pediatric patients with ADHD who have a prescription from a healthcare provider, due to the increased age range.

The digital treatment offers an immersive video game experience that is created by world-class neuroscientists and award-winning game designers that can be accessed on mobile devices.

According to the EndeavorRx website, the tool uses sensory stimuli and motor challenges to target areas of the brain that play a key role in attention function.

Kids are challenged to multitask and ignore distractions by navigating courses, collecting targets and avoiding obstacles.

An algorithm measures performance and customizes each patient’s treatment in real time. Parents can also follow their child’s treatment and track daily efforts through the Endeavor app.

It's recommended to play for no more than 25 minutes, 5 days a week for at least 4 consecutive weeks, or as prescribed.

A similar Akili tool, EndeavorOTC™, is also offered to adults with ADHD.

The FDA’s label expansion is based on a clinical study that involved 162 adolescents with a verified diagnosis of inattentive or combined-type ADHD who all received EndeavorRx for 4 weeks and subsequently demonstrated significant improvements in Test of Variables of Attention (TOVAⓇ)-measured* attentional control.

Scott Kollins, MD, PhD, chief medical officer at Akili, said in a press release, the study for adolescents “demonstrates that EndeavorRx is a safe and effective treatment option for millions of kids and teens struggling with ADHD – particularly important given the ongoing stimulant medication shortage.”

Additionally, this study revealed that adolescents using EndeavorRx also saw significant improvement in clinician-rated ADHD symptoms, as measured by the Attention Deficit Hyperactive Disorder Rating Scale-5 (ADHD-RS) inattention subscale and total scale scores.

ADHD-RS is a clinician-administered questionnaire based on information collected from the child's caregiver.

Following treatment, participants in the study showed significant improvement on both the inattention subscale and total score of the ADHD-RS (p<0.0001 for both).

A prespecified responder analysis also showed that 27.1% of all participants in the study demonstrated at least a 30% reduction in total scores on the ADHD-RS, similar to the initial STARS-ADHD trial in 8- to 12-year-old children with ADHD (24%).

Significant improvements were also observed for parent and child ratings of attention improvement, as well as parent ratings of function across domains such as peer relationships, academic functioning, behavioral functioning, homework functioning and self-esteem.

Overall, four (2.5%) participants experienced a treatment-emergent adverse device event, including three decreased frustration tolerance and one headache ‑ all mild or moderate.

There were no serious adverse device events, the study reported.

Related Videos
Video 6 - "Navigating Insurance Coverage for Prescription Digital Therapeutics"
Video 5 - "FDA Approval Pathway for Prescription Digital Therapeutics"
Video 8 - "Gaps in Evidence Generation for Digital Therapeutics"
Video 7 - "Adoption Lessons For Payers"
Video 4 - "Assessing the Cost-Effectiveness of Prescription Digital Therapeutics "
Video 3 - "Harnessing Prescription Drug Therapeutics as Monotherapy and Adjunct Therapy"
Video 6 - "Developing Reimbursement Models for Digital Therapeutics"
Video 5 - "Cost-Effectiveness Metrics Payers Seek for Digital Therapeutics"
Video 2 - "Bridging Care Gaps with Prescription Digital Therapeutics"
Video 1 - "Overview of Prescription Digital Therapeutics and Impact on Clinical Practice"
Related Content
© 2024 MJH Life Sciences

All rights reserved.